Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT03792256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03792256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
April 11, 2019
Completion date
September 30, 2023
Enrollment
12 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, leukemia, lymphocytic, lymphoblastic lymphoma, recurrent disease, t-cell leukemia, t-cell lymphoma